 This is a Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care SL BPN in initiation and maintenance treatment with BPN. The trial will involve 4 phases: Screening, Phase 1 weekly visits, Phase 2 monthly visits, and Follow-up. 